Payers Expect Clearer Demonstration of Health Technology Benefits
Sweden and Finland are leaders in developing and applying health technology and provide ideal environments for conducting Health Technology Assessments (HTA) for medical devices.
Latest News
Current topics from the world of pharmaceuticals, healthcare and research. Make sure to also check out our RWE-themed blog!
Latest articles
-
-
Medaffcon Brings RWE from the Nordic Markets for Global Use
Medaffcon's operations in Sweden are well-established and growing, offering pharmaceutical companies RWE studies and Market Access services delivered by Data Scientists, Market Access experts, and RWE specialists working together. A key therapeutic area is oncology.
-
RWE Study: Prognosis for Multiple Myeloma has Improved, but Prevalence is Increasing
The prognosis for patients with multiple myeloma (MM) has improved as treatments have advanced, but the disease remains incurable. The prevalence of the disease is increasing in Finland as the population gets older. This is evident from a recently published nationwide retrospective study based on real-world evidence (RWE).
-
RWE Study Shows: New Diabetes Medications Were Actively Adopted Between 2012–2019 – The Results Are Promising
The adoption of new diabetes medications in Finland was active between 2012 and 2019, according to an RWE (Real World Evidence) study published in May 2024. The study was conducted by Medaffcon in collaboration with the pharmaceutical company Sanofi.
-
Medaffcon is Preparing to Conduct RWE Studies in Neurology and Psychiatry
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life. Medaffcon is contributing to this development by conducting, for example, RWE studies (Real World Evidence).
-
Medaffcon’s scientific expert’s day includes a variety of activities tailored to the needs of the pharmaceutical industry
Medaffcon experts are versatile professionals who adapt to customer needs. In this article, one of them, Liisa Ukkola-Vuoti, a senior scientific advisor at Medaffcon, describes her work over two weeks. Liisa is also one of the writers for the Health Data Site by Medaffcon.
Most popular articles
-
Medaffcon is Preparing to Conduct RWE Studies in Neurology and Psychiatry
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life. Medaffcon is contributing to this development by conducting, for example, RWE studies (Real World Evidence).
-
An Epidemiologist / Scientific Advisor
Medaffcon Oy is an Espoo, Finland, based Real World Evidence, Medical Affairs and Market Access consulting company providing services in Finland and Sweden. As of May 2024, Medaffcon’s personnel consists of some 30 full-time employees. Medaffcon’s core competences are our strong medical, scientific, industrial and health economic knowledge and experience, outstanding process and project management and our wide-ranging cooperation network. We at Medaffcon dive into our clients' challenges and customise practical solutions for them.
-
EHDS makes Finland an even more attractive place for RWE research
Finland will become an even more attractive place for conducting RWE (real-world evidence) research when it becomes a seamless part of the European Health Data Space (EHDS). Thus, health data can be used more efficiently across the European Union (EU), and datasets can be combined on an EU-wide basis.
-
Heikki Koski Appointed as CEO of Medaffcon Oy
Heikki Koski, currently the Service Business and Development Director at Tamro, has been appointed as the CEO of Medaffcon Oy, effective from April 1, 2024. Medaffcon is a subsidiary of Tamro Oyj. The current CEO of Medaffcon, Jarmo Hahl, will continue to play a pivotal role in shaping the company's future in his new position leading the consulting business.
-
Medaffcon has in-depth Understanding of the Needs of the Pharmaceutical Industry –
Selecting the right interactions is a key factor for success. Therefore, the client should also consider how well the partner understands the pharmaceutical industry's needs. When the partner has extensive hands-on experience from the industry, these irreplaceable insights enable the partner to guide the project at different strategic levels, ensuring that the client’s various needs can be identified and met.
-
The OMOP (Observational Medical Outcomes Partnership) Common Data Model (CDM) facilitates the utilization of healthcare data – Medaffcon was involved in a Finnish OMOP pilot study
In healthcare, there is a vast amount of data being generated and processed. Sometimes, its utilization is cumbersome because the data is scattered, and its analysis requires a lot of preprocessing.
Health Data Site by Medaffcon
-
Medaffcon’s scientific expert’s day includes a variety of activities tailored to the needs of the pharmaceutical industry
Medaffcon experts are versatile professionals who adapt to customer needs. In this article, one of them, Liisa Ukkola-Vuoti, a senior scientific advisor at Medaffcon, describes her work over two weeks. Liisa is also one of the writers for the Health Data Site by Medaffcon.
-
Real-World Evidence (RWE) Influences Treatment Practices – Developing the Current Care Guidelines for Heart Failure
My list of publications includes over 20 peer-reviewed scientific articles. One of them is a special one because the Finnish Current Care Guidelines mention it for heart failure. This blog discusses the impact of research by Medaffcon on treatment practices.
-
We are remodeling the Health from Data Blog – The new name is “Health Data Site by Medaffcon”, and it will have a fragment in our Newsletter
We are remodeling the Health from Data Blog – The new name is "Health Data Site by Medaffcon", and it will have a fragment in our Newsletter
-
Health from Data takes a look at the past and the future
Health from Data blog was founded in 2021. It’s the third year and this is…
-
RWE provides information for many needs
Real-world evidence (RWE) studies are usually started with a specific use for results in mind….
-
World of methodologies | Virtual control arms provide more data for decision making
Recently, there has been a lot of discussion on virtual control arms. In this blog…